Ocugen, Inc. (OCGN)

Market Cap	628.49M +256.0%
Revenue (ttm)	4.41M +8.8%
Net Income	-67.85M
EPS	-0.23
Shares Out	337.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,580,378
Open	1.860
Previous Close	1.740
Day's Range	1.840 - 1.920
52-Week Range	0.570 - 2.725
Beta	2.81
Analysts	Strong Buy
Price Target	9.75 (+424.19%)
Earnings Date	May 8, 2026

About OCGN

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: OCGN
• Website: https://www.ocugen.com

Financial Performance

In 2025, Ocugen's revenue was $4.41 million, an increase of 8.83% compared to the previous year's $4.06 million. Losses were -$67.85 million, 25.5% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for OCGN stock is "Strong Buy." The 12-month stock price target is $9.75, which is an increase of 424.19% from the latest price.

Price Target

$9.75

(424.19% upside)

Analyst Consensus: Strong Buy